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Abstract
Salivary and mammary gland tumors show morphological similarities and share 
various characteristics, including frequent overexpression of hormone receptors 
and female preponderance. Although this may suggest a common etiology, it re-
mains unclear whether patients with a salivary gland tumor carry an increased risk 
of breast cancer (BC). Our purpose was to determine the risk of BC in women di-
agnosed with salivary gland carcinoma (SGC) or pleomorphic adenoma (SGPA). 
BC incidence (invasive and in situ) was assessed in two nationwide cohorts: one 
comprising 1567 women diagnosed with SGC and one with 2083 women with 
SGPA. BC incidence was compared with general population rates using stand-
ardized incidence ratio (SIR). BC risk was assessed according to age at SGC/
SGPA diagnosis, follow-up time and (for SGC patients) histological subtype. The 
mean follow-up was 7.0 years after SGC and 9.9 after SGPA diagnosis. During 
follow-up, 52 patients with SGC and 74 patients with SGPA developed BC. The 
median time to BC was 6  years after SGC and 7 after SGPA. The cumulative 
risk at 10  years of follow-up was 3.1% after SGC and 3.5% after SGPA (95% 
Confidence Interval (95%CI) 2.1%–4.7% and 2.6%–4.6%, respectively). BC inci-
dence was 1.59 times (95%CI 1.19–2.09) higher in the SGC-cohort than expected 
based on incidence rates in the general population. SGPA-patients showed a 1.48 
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1 |  INTRODUCTION
Major salivary gland cancer (SGC) and salivary gland pleo-
morphic adenoma (SGPA) together constitute almost three 
quarters of all salivary gland tumors, and have a yearly in-
cidence of respectively 0.7 and 4.9/100,000 person-years in 
the Netherlands (European Standardized Rate).1,2 Benign sal-
ivary gland tumors occur 6–7 times more frequently than ma-
lignant tumors and the SGPA, which accounts for two thirds 
of all benign salivary gland tumors, may occasionally show 
malignant transformation.2–6
Salivary and mammary gland tumors show morphologi-
cal similarities and salivary gland-like type tumors have been 
described in the breast.7–11 They also share other character-
istics, including frequent overexpression of hormone recep-
tors and in some histologies a female preponderance, most 
consistently in salivary gland adenoid cystic carcinoma and 
SGPA.1–3,12–16
Whereas the larger amount of glandular breast tissue 
(next to hormonal, lifestyle, and genetic factors) puts women 
at higher risk of BC than men, gland volume does not ex-
plain the higher risk of a salivary gland tumor in women, 
since there are no gender differences in salivary gland size.17 
Differential attitudes toward physical appearance or towards 
medical attention seeking behavior between males and fe-
males are unlikely to play a major role in explaining gender 
variation in incidence of SGC and SGPA, due to visibility of 
the tumor.18–20
Although the similarities may suggest a common eti-
ology, it remains uncertain whether patients with a sali-
vary gland tumor carry an increased risk of breast cancer 
(BC). Literature is inconclusive regarding whether risk is 
increased, and if so, to what extent and in which patients. 
A previous salivary gland tumor as a risk factor for BC has 
been reported in the literature, but studies are ambiguous, 
possibly due to the variation in sample size and inclusion 
criteria.21–28 Support for a hormonal component in salivary 
gland cancer risk was earlier reported in an epidemiologi-
cal study, and a hormonal influence could also have played 
a role in the recently reported higher risk of SGC in women 
after BC.29,30
The objective of this study was to determine whether 
women diagnosed with a SGC or SGPA have an increased 
risk of developing BC in two nationwide population-based 
cohorts with long term follow-up and complete cancer inci-
dence data.
2 |  MATERIALS AND METHODS
2.1 | Cohorts
To assess the association between salivary gland tumors 
and BC risk in women, we used two nationwide Dutch reg-
istries. The Netherlands cancer registry (NCR) was used to 
establish a cohort including all incident malignant major 
salivary gland tumors (ICD-O-3 codes: C07: Parotid; C08: 
other and unspecified major salivary gland), diagnosed in 
the Netherlands between 1 January 1989 and 31 December 
2014, without limitations regarding inclusion by age or 
previous other malignancies. All subsequent ductal in 
situ as well as invasive first BCs, registered in the NCR, 
which occurred until 31 December 2014 in this cohort were 
identified. The NCR receives its data mainly from the na-
tionwide histopathology and cytopathology network and ar-
chive in The Netherlands (PALGA- in Dutch: Pathologisch 
Anatomisch Landelijk Geautomatiseerd Archief), but also 
from hospital discharge diagnosis registries (e.g. patients 
with a clinically or radiologically diagnosed SGC, who 
did not undergo biopsy or surgical treatment). Vital sta-
tus and in situ and invasive breast cancer incidence were 
complete until 31 December 2014. Treatment details were 
reported and usually included surgery with post-operative 
radiotherapy in selected cases. The latter typically con-
sists of external beam radiotherapy, which is usually up 
to 70 Gray (Gy) on the tumor and 50 Gy on the neck, and 
has a horizontal direction and stays above the clavicle. 
For the SGPA cohort, we selected all women from a pre-
viously established SGPA cohort that included all Dutch 
pathologically confirmed incident SGPA diagnoses in the 
PALGA registry between 1 January 1992–31 December 
2012 with (for logistical reasons to reduce the size of the 
cohort) a 5-year interval.2 Therefore, all included SGPA 
patients were from the years 1992, 1997, 2002, 2007, and 
2012. PALGA records all cytological and histological di-
agnoses, including those of benign diseases like SGPA, 
times (95%CI 1.16–1.86) higher incidence. Women with SGC or SGPA have a 
slightly increased risk of BC. The magnitude of risk justifies raising awareness, 
but is no reason for BC screening.
K E Y W O R D S
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and has complete coverage of the Netherlands since 1991. 
PALGA is one of only a few national registries worldwide 
that include benign tumors, which allowed establishing 
our nationwide SGPA cohort.2,3 The Palga registry does 
not contain standardized information on therapy. However, 
all patients in this cohort had a histological diagnose, thus 
had surgery. Radiotherapy is typically applied in selected 
recurrent SGPA cases. All subsequent DCIS as well as all 
invasive first BCs, registered in PALGA, which occurred 
until 31 December 2013 in this cohort were identified. 
Basal cell carcinoma and melanoma of the breast were ex-
cluded. Patients with BC before SGC or SGPA were ex-
cluded as well.
2.2 | Statistical analysis
Time at risk started at date of SGC or SGPA diagnosis. For 
SGC follow-up ended at the date of BC diagnosis, death, 
emigration, or last follow-up, whichever came first. In SGPA 
patients, the expected number of cases and cumulative risk 
of BC were based on the cumulative follow-up time. Since 
vital status is not registered in the PALGA registry, mortality 
among SGPA patients was imputed using gender-, age-, and 
calendar-year specific life-tables for the Dutch population, 
generating 50 imputed datasets, under the assumption that 
SGPA patients, as SGPA is a benign disease, had a similar 
life expectancy as the Dutch general population. Estimated 
cumulative risks and standard errors in each imputed dataset 
were subsequently pooled using Rubin's rule.
Expected BC incidence in the SGC cohort was estimated 
using the Hakulinen method.31 The Standardized Incidence 
Ratio (SIR) was calculated as the ratio between the observed 
and expected number of BC cases in both the SGC-cohort and 
the SGPA-cohort. In order to compare the observed BC inci-
dence in our study population with the BC incidence among 
Dutch females from the general population, we used exter-
nal reference rates. Using age-specific (5-year age groups) 
and calendar-year specific BC incidence rates for the Dutch 
female population, we calculated the number of BCs we 
could have expected if our cohort would have had the same 
age-specific BC incidence as the general population, based 
on the number of person-years of follow-up our women ac-
crued in each 5-year age group during each year of follow-up. 
This method of using external data as reference data has been 
extensively used previously.32 Thus, the number of BC cases 
in both the SGC-cohort and the SGPA-cohort are compared 
with BC cases in a contemporized follow-up period in con-
temporized age categories, in the Dutch population.
As a sensitivity analysis, the SIR was also determined 
for BCs occurring ≥3 months after the index salivary gland 
tumor, thereby excluding potential synchronous BC. In this 
analysis time at risk started at 93 days after SGC or SGPA 
diagnosis. Also, as a sensitivity analysis risk of invasive and 
in situ BC was evaluated separately. BC risk was also as-
sessed and stratified for SGC/ SGPA age, follow-up time and 
(in SGC patients) histological subtype. For SGC patients the 
5 and 10-year survival after BC was calculated, with a sub-
group analysis for patients younger than 65 years. The 95% 
confidence intervals (95%CI) were calculated assuming a 
Poisson distribution for the observed number of events. Tests 
for homogeneity and trend of SIRs were performed using 
Poisson regression models based on collapsed person-time 
data. Statistical analysis was performed using STATA 13 
(StataCorp LP).
3 |  RESULTS
Our study included 3650 women: 1567 women with SGC and 
2083 women with SGPA, translating into a yearly mean of 60 
and 417 women respectively (Table 1; Table S2). The over-
all median age at diagnosis of the salivary gland tumor was 
56  years (IQR 45–68). The median follow-up was 7  years 
(IQR 2–12) after SGC. The median follow-up after an SGPA 
diagnosis was 6 years (IQR 2–16). During follow-up 52 SGC 
patients developed BC, of whom 46 (88%) had invasive and 
6 (12%) in situ BC (Table 2; Table S3). Of the SGPA pa-
tients 74 developed BC, of whom 68 (92%) had invasive and 
6 (8%) in situ BC. Overall, the median age at BC diagno-
sis was 63 years (IQR 51–74). The median interval between 
salivary gland tumor and BC diagnosis was 6 years in SGC 
(range 0–24; IQR 3–9) and 7 years (range 0–20; IQR 3–11) in 
SGPA. In SGC patients, the 5- and 10-year survival rate after 
invasive BC was respectively 59.8% (95%CI 42.7–73.4%) 
and 42.0% (95%CI 24.9%–58.1%). For patients younger than 
65 years, this was 78.9% (95%CI 52.4%–91.7%) and 70.1% 
(95%CI 40.5%–87.0%). The BC receptorstatus could be de-
termined in most cases (Table 2).
3.1 | Comparison with the 
general population
The cumulative risk of BC in SGC patients was 5.3% (95% CI 
3.8%–7.3%) at 10 and 8.2% (95% CI 5.8%-11.5%) at 20 years, 
respectively (Table 3). The comparison to the expected risk 
based on the general population of 2.9% at 10 years and 6.0% 
at 20 years (dotted line) is made in Figure 1A. The cumu-
lative risk of BC among SGPA patients was 3.5% (95% CI 
2.6%–4.6%) at 10  years and 7.2% (95% CI 5.4%–9.4%) at 
20 years, respectively (Table 3). In comparison, the expected 
cumulative BC risk, based on age-matched incidence in the 
general population, was 2.2% at 10 and 5.2% at 20  years, 
respectively (Figure 1B). Overall, among SGC patients the 
incidence of BC was 1.59 times (95% CI 1.19–2.09) higher 
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than expected based on general population rates. BC inci-
dence was 1.48 times (95% CI 1.16–1.86) higher than ex-
pected among SGPA patients. The SIRs when risk of DCIS 
and invasive BC in the SGC-cohort were estimated separately 
were similar (SIR 1.86 for in situ BC; 95% CI 0.68–4.04 and 
SIR 1.57 for invasive BC; 95% CI 1.14–2.09, respectively). 
SIRs for BC (invasive or in situ) did not vary with age at 
SGC diagnosis (SIR <50  years: 1.54, 95% CI 0.79–2.68; 
SIR 50–69 years: 1.69, 95% CI 1.10–2.48; SIR ≥70 years: 
1.48, 95% CI 0.81–2.49, p-heterogeneity = 0.91) nor did they 
change with follow-up duration (SIR <10 years: 1.76, 95% 
CI 1.28–2.38; SIR 10–19 years: 0.92, 95% CI 0.37–1.89; SIR 
≥20 years: 2.70, 95% CI 0.56–7.90, p-heterogeneity = 0.19) 
or histological SGC subtype (Table 3). For SGPA patients, 
BC incidence did neither vary with age at SGPA diagnosis 
nor with follow-up duration. A sensitivity analysis, showed 
similar risks after exclusion of synchronous BC (n = 4), de-
fined as all BC diagnosed <3 months after the salivary gland 
tumor diagnosis; the SIR was 1.57; (95% CI 1.14–2.09) for 
SGC and 1.33 (95% CI 1.04–1.64) for SGPA, respectively.
In the SGC-cohort, the absolute excess risk (AER) of 
DCIS and invasive BC combined was 17.7, in other words 
T A B L E  1  Population characteristics of the salivary gland carcinoma (SGC) or salivary gland pleomorphic adenoma (SGPA) with and without 
subsequent breast cancer (BC)
SGC SGPA
Subsequent BC (n = 52) No subsequent BC (n = 1515) BC (n = 74) no BC (n = 2009)
Age at diagnosis, yearsb (IQR) 57 (49–69) 63 (47–75) 50 (42–66) 48 (37–63)
Year of salivary tumor diagnose
1989–1994 13 282 22 321
1995–2004 25 557 37 746
2005–2013 14 676 15 942
Histology SG tumora , N(%)
Adenoid cystic ca. 9 (17.3) 305 (20.1)
Muco-epidermoid ca. 9 (17.3) 227 (15)
Acinic cell ca. 9 (17.3) 263 (17.4)
Ca. ex Pleomorphic Adenoma 6 (11.5) 106 (7)
Adenocarcinoma., NOS 7 (13.5) 204 (13.5)
Squamous cell ca. 2 (3.8) 95 (6.3)
Myo-epithelial ca. 4 (7.7) 95 (6.3)
Salivary duct ca. 1 (1.9) 29 (1.9)
Other salivary gland ca. 5 (9.6) 190 (12.5)
Pleomorphic adenoma 74 (100) 2009 (100)
Stage, N (%) NA NA
I 15 (28.8) 436 (28.8)
II 10 (19.2) 226 (14.9)
III 4 (7.7) 163 (10.8)
IV 5 (9.6) 328 (21.7)
Unknown/unavailable 18 (34.6) 362 (23.9)
Treatment SG tumor N (%)
Surgery with radiotherapy 27 (51.9) 881 (58.2) 74 (100.0) 2083 (100)
Surgery only 13 (25) 359 (23.7)
Radiotherapy only 3 (5.8) 91 (6)
No therapy 3 (5.8) 76 (5)
Surgery+radiotherapy+other 5 (9.6) 41 (2.7)
Other 0 (0) 42 (2.8)
Unknown/unavailabe 1 (1.9) 25 (1.7)
Abbreviation: NA, not applicable.
aHistology ICD-O 3.1 Codes are shown in Table S2. 
bMedian. 
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17.7 excess BC for every 1000 women, each followed for 
10 years. In the SGPA-cohort the AER was 12.8 per 10,000 
person-years.
4 |  DISCUSSION
In this large and nationwide study with long-term complete 
follow-up, including 3650 women diagnosed with SGC and 
SGPA, the risk of developing a subsequent BC is moderately 
increased. This roughly 50% higher relative risk of BC can 
be better interpreted by mentioning absolute numbers in 
an example. For a 50-year-old woman, the risk to develop 
breast cancer in the next 10 years (until the age of 60) equals 
2.9%.33 After a previous diagnosis with SGC or SGPA, this 
risk would be 4.3%.
In contrast to many previous studies on BC risk after a sal-
ivary gland tumor, the nationwide cohorts used in our study 
either consisted solely of malignant or of benign tumors. The 
high number of patients allowed unbiased estimation of rela-
tive and absolute risk in both type of lesions and gave rise to 
the possibility of subgroup analysis.
The lower age at diagnosis of second tumors in the SGPA-
cohort compared to the SGC-cohort (Table 2), was in line 
with the lower age of the SGPA patients and earlier publica-
tions.1,2 The increased BC risk after SGC or SGPA did not 
vary much with age at index tumor diagnosis nor with SGC 
histological subtype. The finding of an increased risk in pa-
tients diagnosed with BC ≥3 months after the salivary gland 
tumor, showed that the increased BC incidence was not likely 
based on surveillance bias caused by diagnostic evaluation of 
the index tumor.
Results of previous studies varied from no risk increase 
upto 8-fold increased risks (Table 4). Many of these studies 
had methodological shortcomings which made comparison 
and generalization of these results difficult.21–28 For instance, 
most studies did not provide a confidence interval for the risk 
estimates presented.23–26,28 The completeness of follow-up 
may have been a problem in single institution cohorts.21,22,28 
Missing a diagnosis of even one patient with a second pri-
mary BC, would have had a substantial negative impact on 
the estimated risk in these cohorts which included between 
4 and 15 BC cases each. Also, there could be a referral bias 
in comprehensive cancer centers, because of inclusion of a 
higher proportion of patients with second or multiple prima-
ries. Variation in BC incidence between the USA and Europe 
unlikely explains the high risk in two American studies.21,26 
Additionally, BC incidence rates in the SEER registry are 
generally lower than in European populations.34 A later con-
ducted population based SEER study could not confirm the 
reported higher BC risk after an earlier SGC (SIR 1.07; 95% 
CI 0.72–1.53).27 This absence of an increased risk could 
have been caused by differences in inclusion, by including 
lesions of undefined histology (overall 25%) as a first tumor. 
These could have been metastases of, for example, squamous 
cell carcinoma of the skin of the face or skull to the parotid, 
which could have attenuated a higher risk of BC.
The increased risk of BC after a salivary gland tumor in 
our nationwide cohorts, is of similar magnitude as some of 
the known risk factors, such as alcohol intake or use oral con-
traceptives (Table S1) and is remarkable. It could theoreti-
cally be caused by several mechanisms.
T A B L E  2  Breast cancer (BC) histology and receptor status of 
patients with a salivary gland carcinoma (SGC) or salivary gland 





Year of BC diagnose, N (%)
1989–1994 2 (3.8) 23 (31.1)
1995–2004 11 (21.2) 37 (50)
2005–2014 39 (75) 14 (18.9)
Age at diagnosis
Median, years (IQR) 64 (57–76) 61 (50–69)
<50 6 (11.5) 17 (23)
50–69 25 (48.1) 38 (51.4)
>70 21 (40.3) 19 (25.7)
Histology BCa , N (%)
Invasive carcinoma
Lobular carcinoma 6 (11.5) 5 (6.7)
Ductal/Adeno 
carcinoma
39 (75) 57 (77)
Other BC (e.g. undiff. 
/ NOS)
1 (1.9) 6 (8.1)
In situ carcinoma
DCIS 6 (11.5) 6 (8.1)
Receptor status, N (%)
ER+b 28 (53.8) 51 (68.9)
ER– 8 (15.4) 11 (14.9)
ER unknown 16 (30.8) 12 (16.2)
PR+c 22 (42.3) 39 (52.7)
PR– 11 (21.2) 19 (25.7)
PR unknown 19 (36.5) 16 (21.6)
Her2neu+d 6 (11.5) 8 (10.8)
Her2neu– 14 (26.9) 40 (54.1)
Her2neu unknown 32 (61.5) 26 (35.1)
Abbreviation: NA, not applicable.
aHistology ICD-O 3.1 Codes are shown in Table S3. 
bEstrogen receptor. 
cProgesteron receptor. 
dHuman Epidermal growth factor Receptor 2. 
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4.1 | Common endocrine mechanism and 
common environmental / lifestyle factors
A positive association between (high levels of) endogenous 
estrogens or estrogen exposure and risk of various female 
cancers (breast, ovarian and endometrial cancer) has been 
consistently described in the epidemiological literature.35–38 
Estrogens are thought to cause this increased cancer risk 
via cell proliferation, DNA-damage (as a result of estradiol 
metabolism to genotoxic metabolites) and inhibition of cell 
repair mechanisms.39 Estrogen exposure may have similar 
effects on salivary glandular tissue, which also expresses es-
trogen receptors. It could therefore be that women with high 
endogenous estrogen levels (e.g. in post-menopausal high 
BMI) or exposure (e.g. in postmenopausal hormone replace-
ment therapy or use of oral contraceptives) have an increased 
risk of SGC or SGPA.40–44 If estrogen indeed has an effect on 
both risk of SGC and risk of SGPA, this could also explain 
the reported female preponderance of SGC and SGPA. In the 
literature, generally only a small portion of salivary gland tu-
mors show ER-overexpression based on immunohistochem-
istry, possibly because mainly ER-α and not ER-β expression 
status has been assessed.45–51 Nevertheless, although ER-β 
expression in salivary gland tumors was only reported in a 
limited number of series, ER-β was overexpressed in 27 of 38 
(71%) patients in a series of adenoid cystic carcinomas and 
in 57 of 80 (73%) in a series of salivary duct carcinomas.16,52
In SGPA and adenoid cystic carcinoma, the slight, but 
relevant difference in incidence between males and females 
(female to male incidence ratio of 1.4:1 and 1.2:1, respec-
tively) and the overexpression of estrogen β receptor (ER-β), 
compared to normal salivary gland, may suggest a role for the 
proliferative influence of estrogens in tumorigenesis.2,14,53 
Similar considerations have been mentioned in earlier reports 
F I G U R E  1   The cumulative risk of in situ and invasive breast 
cancer over a 20-year period is increased after both salivary gland 




T A B L E  4  A comparison of publications investigating breast cancer (BC) incidence in women after diagnosis of a salivary gland tumour (SGT)




risk Observed BC Expected BC
O/E 
(SIR) p value 95% CI
196821 396 M 1652 7 0.9 7.8 0.00004 NR
196922 297 M 3033 4 4.0 1.0 NA NA
197223 349 M 2443 8 4.2 1.9 0.6 NR
197724 453 M + B 2315 6 2.6 2.3 <0.05 NR
198325 367 M 2868 7 5.4 1.3 NR 0.5–2.7
198426 190 M + B 629 4 0.83 4.8 0.01 NR
199927 1718 Ma 10,789 30 28 1.07 NR 0.72–1.53
200528 439 M + B 3382 15 5.93 2.5 0.003 1.4–4.2
Current 2083 B 18,852 74 50 1.48 NR 1.16–1.86
2019 1567 M 10,995 52 32.6 1.59 NR 1.19–2.09
Abbreviations: B, benign; M, malignant; NA, not applicable; NR, not reported.
a25% undetermined / mixed histology and 13% squamous cell carcinoma. 
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of experimental anti-estrogen treatment for SGC in the liter-
ature.8,54,55 From the above, it could be concluded it is a re-
alistic possibility that estrogens play a role in the association 
between salivary gland tumors and BC.
4.2 | Salivary gland tumor 
treatment or metastasis
It is unlikely that SGC of SGPA treatment contributes to an 
increased BC risk since locoregional treatment does not af-
fect breast tissue. In external beam radiotherapy for SGC, the 
breast is not an organ at risk due to the direct dose, although 
scattered radiation could in theory add to the risk of primary 
breast cancer. This dose can be calculated.56 After radiother-
apy for SGC in the earlier mentioned example of a 50-year 
old female patient, this estimated additional lifetime risk is 
0.3%, for all cancers. So, scattering does not contribute sub-
stantially to the risk of BC.
An increased BC risk due to SGC chemotherapy (de-
pending on histology, but mostly cisplatin based) is not very 
likely.57,58 Solitary metastasis of SGC to the breast is not very 
likely. The SGPA is known to almost never metastasize at all. 
Also, if there were cases, these would probably have been 
recorded in the pathology database or cancer registry not as 
BC but as metastasized salivary gland tumor.
4.3 | Common genetic susceptibility
Germline mutations that could account for the occurrence of 
both a salivary gland tumor and BC in the same woman have 
not been identified yet, and the literature on this topic is lim-
ited. One retrospective study including 5754 proven or likely 
carriers from 187 BRCA1 or BRCA2 positive pedigrees, re-
ported three SGCs.59 Although the authors reported an in-
creased SGC incidence, a 95% CI was not provided. Mersch 
and colleagues did not find any SGC in 1072 patients with a 
BRCA1 or BRCA2 mutation, who had received genetic coun-
selling.60 In a study of 268 patients with SGPA, upon evalu-
ation for BRCA1, one had a BRCA1 mutation (who earlier 
also had BC).61 Other forms of genetic predisposition, that is, 
based on (multiple) single-nucleotide polymorphisms (SNPs) 
have not been reported. Although SGPA is characterized by a 
chromosomal translocation that causes activation of the pleo-
morphic adenoma gene 1 (PLAG1) on chromosome 8q12, 
germline mutations have not yet been identified.62–66
4.4 | Limitations
Although the results of this study suggest that sali-
vary gland tumors and BC share a common (hormonal) 
etiological factor, further investigation will be needed to 
provide more insight in the underlying mechanism. It is 
still unclear whether affected women who develop both 
a salivary gland tumor and BC are, for example, more 
susceptible for the effect of estrogens, have higher blood 
levels or have had more estrogen exposure. Data on BC 
risk factors were unavailable as these are not routinely col-
lected by the Dutch cancer registry.
Person time after an SGPA diagnosis was not available 
and imputed assuming these patients had a similar life expec-
tancy as the general Dutch population. SGPA does carry a 
very small risk of malignant transformation of approximately 
0.15%, which may lead to a slightly higher mortality than 
that of the general population.2 We may thus have overesti-
mated the follow-up in the SGPA cohort, which would have 
resulted in slight overestimation of the expected number of BC 
cases,2 and subsequently an underestimation of the SIR for BC. 
Follow-up of SGC patients is very complete, with information 
on dates of death or migration provided by linkage with the 
Dutch nationwide population registry, and near complete in-
formation on BCs occurring in this cohort, available from the 
same source.
In summary, there are some indications that suggest an 
endocrine mechanism behind the increased incidence of BC 
in salivary gland tumours. Data on a possible genetic back-
ground are insufficient. Sequencing of the cohorts for possible 
germline mutations might provide further clues regarding ge-
netic predisposition, but this would require very large cohorts.
4.5 | Clinical implications
Women with a SGC or SGPA have a moderately increased 
risk of BC, compared to women in the general population. 
The relative risk for BC in patients with SGC or SGPA (to-
gether almost 75% of salivary gland tumors) is of similar 
magnitude as in patients who have one of various classical 
BC risk factors. However, the magnitude of the relative 
risk is no reason for recommending an intensified follow-
up schedule. Nevertheless, our study should raise aware-
ness of a slightly increased risk of developing BC among 
female patients diagnosed with SGC or SGPA and their 
treating physicians.
ACKNOWLEDGEMENTS
The authors thank the registration team of the Netherlands 
Comprehensive Cancer Organization (IKNL) for the col-
lection of data for the Netherlands Cancer Registry and the 
Dutch pathologists and PALGA foundation. Also we thank 
dr. Jeroen B. van de Kamer and dr. Wouter V. Vogel for their 
contribution in calculating the scattered radiation dose in ra-
diotherapy to the salivary glands and the additional lifetime 
risk of cancer.
   | 9VALSTAR eT AL.
AUTHOR CONTRIBUTIONS
Matthijs Valstar: conceptualization, data curation, formal 
analysis, investigation, methodology, project administration, 
resources, validation, visualization, writing - original draft. 
Michael Schaapveld: data curation, formal analysis, inves-
tigation, methodology, resources, validation, visualization, 
writing—review and editing. Esther van den Broek: con-
ceptualization, data curation, formal analysis, investigation, 
methodology, project administration, resources, writing—re-
view and editing. Marie-Louise van Velthuysen: conceptual-
ization, data curation, writing—review and editing. Mischa de 
Ridder: conceptualization, data curation, methodology, pro-
ject administration, writing—review and editing. Marjanka 
Schmidt: interpretation of data, writing—review and edit-
ing. Boukje van Dijk: data curation, methodology, resources, 
validation, visualization, writing—review and editing. Alfons 
Balm: conceptualization, methodology, writing—review and 
editing, supervision. Ludi Smeele: conceptualization, meth-
odology, writing—review and editing, supervision.
ETHICAL APPROVAL
Not applicable; all patient information that was provided to 
the authors, was anonimized beforehand by the two national 
registries, after the research protocol was approved by their 
scientific boards.
DATA AVAILABILITY STATEMENT
Research data are available upon reasonable request.
ORCID
Matthijs H. Valstar   https://orcid.
org/0000-0002-2415-0893 
REFERENCES
 1. de Ridder M, Balm AJM, Smeele LE, Wouters MWJM, van 
Dijk BAC. An epidemiological evaluation of salivary gland 
cancer in the Netherlands (1989–2010). Cancer Epidemiol. 
2015;39:14–20.
 2. Valstar M, de Ridder M, van den Broek E, et al. Salivary gland 
pleomorphic adenoma in the Netherlands: a nationwide obser-
vational study of primary tumor incidence, malignant transfor-
mation, recurrence, and risk factors for recurrence. Oral Oncol. 
2017;66:93–99.
 3. Andreasen S, Therkildsen MH, Bjørndal K, Homøe P. Pleomorphic 
adenoma of the parotid gland 1985–2010: a Danish nationwide 
study of incidence, recurrence rate, and malignant transformation. 
Head Neck. 2016;38:E1364–E1369.
 4. Gnepp D. Malignant mixed tumors of the salivary glands: a review. 
Pathol Annu. 1993;28:279–328.
 5. Przewoźny T, Stankiewicz C. Neoplasms of the parotid gland in 
northern Poland, 1991–2000: an epidemiologic study. Eur Arch 
Otorhinolaryngol. 2004;261:369–375.
 6. Bradley PJ, McGurk M. Incidence of salivary gland neo-
plasms in a defined UK population. Br J Oral Maxillofac Surg. 
2013;51:399–403.
 7. Pia-Foschini M. Salivary gland-like tumours of the breast: surgical 
and molecular pathology. J Clin Pathol. 2003;56:497–506.
 8. Murase R, Sumida T, Ishikawa A, et al. Novel therapeutic strat-
egies for malignant salivary gland tumors: lessons learned from 
breast cancer. Int J Otolaryngol. 2011;2011:1–9.
 9. Camelo-Piragua SI, Habib C, Kanumuri P, Lago CE, Mason HS, 
Otis CN. Mucoepidermoid carcinoma of the breast shares cytoge-
netic abnormality with mucoepidermoid carcinoma of the salivary 
gland: a case report with molecular analysis and review of the lit-
erature. Hum Pathol. 2009;40:887–892.
 10. Marchiò C, Weigelt B, Reis-Filho JS. Adenoid cystic carcino-
mas of the breast and salivary glands (or “The strange case of Dr 
Jekyll and Mr Hyde” of exocrine gland carcinomas). J Clin Pathol. 
2010;63:220–228.
 11. Skálová A, Vanecek T, Sima R, et al. Mammary analogue secre-
tory carcinoma of salivary glands, containing the ETV6-NTRK3 
fusion gene: a hitherto undescribed salivary gland tumor entity. Am 
J Surg Pathol. 2010;34:599–608.
 12. Boukheris H, Curtis R, Land C, Dores G. Incidence of carcinoma 
of the major salivary glands according to the WHO classifica-
tion, 1992 to 2006: a population-based study in the United States. 
Cancer Epidemiol Biomarkers Prev. 2009;18:2899–2906.
 13. Bjørndal K, Krogdahl A, Therkildsen MH, et al. Salivary gland 
carcinoma in Denmark 1990–2005: a national study of incidence, 
site and histology. Results of the Danish Head and Neck Cancer 
Group (DAHANCA). Oral Oncol. 2011;47:677–682.
 14. Wong MHW, Dobbins TA, Tseung J, et al. Oestrogen receptor beta 
expression in pleomorphic adenomas of the parotid gland. J Clin 
Pathol. 2009;62:789–93.
 15. Speirs V. Oestrogen receptor b in breast cancer: good, bad or still 
too early to tell? J Pathol. 2002;197:143–147.
 16. Marques YMFS, Giudice FS, Freitas VM, Abreu e Lima M do 
CC, Hunter KD, Speight PM Machado de Sousa SCO. Oestrogen 
receptor β in adenoid cystic carcinoma of salivary glands. 
Histopathology. 2012;60:609–616.
 17. Dost P, Kaiser S. Ultrasonographic biometry in salivary glands. 
Ultrasound Med Biol. 1997;23:1299–1303.
 18. Micheli A, Mariotto A, Giorgi Rossi A, Gatta G, Muti P. The prog-
nostic role of gender in survival of adult cancer patients. Eur J 
Cancer. 1998;34:2271–2278.
 19. Gove WR, Hughes M. Possible causes of the apparent sex differ-
ences in physical health: an empirical investigation. Am Sociol 
Rev. 1979;44:126–146.
 20. Cleary PD, Mechanic D, Greenley JR. Sex differences in medical 
care utilization: an empirical investigation. J Health Soc Behav. 
1982;23:106–119.
 21. Berg J, Hutter R, Foote F Jr. The unique association between sali-
vary gland cancer and breast cancer. JAMA. 1968;204:771–774.
 22. Moertel C, Elveback L. The association between salivary gland 
cancer and breast cancer. JAMA. 1969;210:306–308.
 23. Dunn J, Kay U, Bragg SC, Gardipee C. Breast cancer risk following 
a major salivary gland carcinoma. Cancer. 1972;29:1343–1346.
 24. Prior P, Waterhouse J. Second primary cancers in patients with 
tumours of the salivary glands. Br J Cancer. 1977;36:362–368.
 25. Biggar R, Curtis R, Hoffman D, Flannery J. Second primary 
malignancies following salivary gland cancers. Br J Cancer. 
1983;47:383–386.
 26. Abbey L, Schwab B, Landau G, Perkins E. Incidence of second 
primary breast cancer among patients with a first primary salivary 
gland tumor. Cancer. 1984;54:1439–1442.
10 |   VALSTAR eT AL.
 27. Sun EC, Curtis R, Melbye MGJ. Salivary gland cancer in the United 
States. Cancer Epidemiol Biomarkers Prev. 1999;8:1095–1100.
 28. In der Maur CD, Klokman WJ, van Leeuwen FE, Tan IB, 
Rutgers EJT, Balm AJM. Increased risk of breast cancer devel-
opment after diagnosis of salivary gland tumour. Eur J Cancer. 
2005;41:1311–1315.
 29. Horn-Ross P, Morrow M, Ljung B. Menstrual and reproductive 
factors for salivary gland cancer risk in women. Epidemiology. 
1999;10:528–530.
 30. Yesensky J, Kyrillos A, Kuchta K, Yao K, Chi-Hsiung W, Bhayani 
M. Risk of development of second primary head and neck cancer 
following an index breast cancer. Otolaryngol - Head Neck Surg. 
2018;158:303–308.
 31. Brenner H, Gefeller O, Hakulinen T. Period analysis for “up-to-
date” cancer survival data: theory, empirical evaluation, computa-
tional realisation and applications. Eur J Cancer. 2004;40:326–335.
 32. Breslow NE, Day NE. Statistical methods in cancer research. 
Volume II--The design and analysis of cohort studies. Breslow NE, 
Day NE, IARC Scientific Publications. 1987;82:1–406.
 33. Dutch Cancer Registry (IKNL). https://www.cijfe rsove rkank er.nl/
selec ties/datas et_1/img5c 52d02 a1f8fa
 34. World Cancer Research Fund and American Institute for Cancer. 
Breast Cancer Report. 2018; Available from: https://www.wcrf.
org/dieta ndcan cer/cance r-trend s/breas t-cance r-stati stics
 35. Brown SBHS. Endogenous estrogens and the risk of breast, endo-
metrial, and ovarian cancers. Steroids. 2015;99(Pt A):8–10.
 36. Folkerd E, Dowsett M. Sex hormones and breast cancer risk and 
prognosis. Breast. 2013;2:S38–43.
 37. Samavat H, Kurzer M. Estrogen metabolism and breast cancer. 
Cancer Lett. 2015;356:231–243.
 38. Chuffa L, Lupi-Júnior L, Costa A, Amorim J, Seiva F. The role of 
sex hormones and steroid receptors on female reproductive can-
cers. Steroids. 2017;118.
 39. Santen R, Yue W, Wang J. Estrogen metabolites and breast cancer. 
Steroids. 2015;99(Pt A):61–66.
 40. Simin J, Tamimi R, Lagergren J, Adami H, Brusselaers N. 
Menopausal hormone therapy and cancer risk: an overestimated 
risk? Eur J Cancer. 2017;84:60–68.
 41. World Health Organization IA for R on C. IARC monographs 
on the evaluation of carcinogenic risks to humans volume 91: 
Combined estrogen-progestogen contraceptives and combined es-
trogen-progestogen menopausal therapy. 2007. 1–528p.
 42. Gierisch J, Coeytaux R, Urrutia R, et al. Oral contraceptive use 
and risk of breast, cervical, colorectal, and endometrial can-
cers: a systematic review. Cancer Epidemiol Biomarkers Prev. 
2013;22:1931–1943.
 43. Lahmann P, Hoffmann K, Allen N, et al. Body size and breast can-
cer risk: findings from the European Prospective Investigation into 
Cancer And Nutrition (EPIC). Int J Cancer. 2004;111:762–771.
 44. Key T, Appleby P, Reeves G, et al. Body mass index, serum sex 
hormones, and breast cancer risk in postmenopausal women. J 
Natl Cancer Inst. 2003;95:1218–1226.
 45. Barrera J, Shroyer K, Said S, et al. Estrogen and progesterone re-
ceptor and p53 gene expression in adenoid cystic cancer. Head 
Neck Pathol. 2008;2:13–18.
 46. Dori S, Trougouboff P, David R, Buchner A. Immunohistochemical 
evaluation of estrogen and progesterone receptors in adenoid cystic 
carcinoma of salivary gland origin. Oral Oncol. 2000;36:450–453.
 47. Nasser S, Faquin W, Dayal Y. Expression of androgen, estrogen, 
and progesterone receptors in salivary gland tumors. Frequent 
expression of androgen receptor in a subset of malignant salivary 
gland tumors. Am J Clin Pathol. 2003;119:801–806.
 48. Pires F, da Cruz PD, de Almeida O, Kowalski L. Estrogen receptor 
expression in salivary gland mucoepidermoid carcinoma and ade-
noid cystic carcinoma. Pathol Oncol Res. 2004;10:166–168.
 49. Shick P, Riordan G, Foss R. Estrogen and progesterone receptors 
in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod. 1995;80:440–444.
 50. Can N, Lingen MW, Mashek H, et al. Expression of hormone re-
ceptors and HER-2 in benign and malignant salivary gland tumors. 
Head Neck Pathol. 2018;12:95–104.
 51. Kolude B, Adisa A, Adeyemi B, Lawal A. Immunohistochemical 
expression of oestrogen receptor-α and progesterone receptor in 
salivary gland tumours. J Oral Pathol Med. 2013;42:716–719.
 52. Williams MD, Roberts D, Blumenschein GR Jr, et al. Differential 
expression of hormonal and growth factor receptors in salivary duct 
carcinomas: biologic significance and potential role in therapeutic 
stratification of patients. Am J Surg Pathol. 2007;31:1645–1652.
 53. Younes M, Honma N. Estrogen receptor β. Arch Pathol Lab Med. 
2011;135:63–66.
 54. Keller G, Steinmann D, Quaas A, Grünwald V, Janssen S, Hussein 
K. New concepts of personalized therapy in salivary gland carci-
nomas. Oral Oncol. 2017;68:103–113.
 55. Elkin A, Jacobs C. Tamoxifen for salivary gland adenoid cys-
tic carcinoma: report of two cases. J Cancer Res Clin Oncol. 
2008;134:1151–1153.
 56. Netherlands Commission on Radiation Dosimetry (NCS). Human 
Exposure to Ionising Radiation for Clinical and Research Purposes: 
Radiation Dose & Risk Estimates. 2016.
 57. Alfieri S, Granata R, Bergamini C, et al. Systemic therapy in met-
astatic salivary gland carcinomas: a pathology-driven paradigm? 
Oral Oncol. 2017;66:58–63.
 58. Lagha A, Chraiet N, Ayadi M, et al. Systemic therapy in the man-
agement of metastatic or advanced salivary gland cancers. Oral 
Oncol. 2012;48:948–957.
 59. Shen TK, Teknos TN, Toland AE, Senter L, Nagy R. Salivary 
Gland Cancer in BRCA -positive families. JAMA Otolaryngol Neck 
Surg. 2014;140:1213.
 60. Mersch J, Jackson MA, Park M, et al. Cancers associated with 
BRCA1 and BRCA2 mutations other than breast and ovarian. 
Cancer. 2015;121:269–275.
 61. Lubiński J, Tarnowska C, Jaworowska E, et al. Pleomorphic ade-
noma of salivary glands does not appear to be a BRCA-1-dependent 
tumour in a Polish cohort. Anticancer Res. 2008;28:3011–3013.
 62. Bullerdiek J, Raabe G, Bartnitzke S, Böschen C, Schloot W. 
Structural rearrangements of chromosome Nr 8 involving 8q12-a 
primary event in pleomorphic ademona of the parotid gland. 
Genetica. 1987;72:85–92.
 63. Mark JDR. Cytogenetical observations in 100 human benign pleo-
morphic adenomas: specificity of the chromosomal aberrations 
and their relationship to sites of localized oncogenes. Anticancer 
Res. 1986;6:299–308.
 64. Debiec-Rychter M, Van VI, Van Den Broeck C, et al. Histologic local-
ization of PLAG1 (Pleomorphic Adenoma Gene 1) in pleomorphic 
adenoma of the salivary gland: cytogenetic evidence of common ori-
gin of phenotypically diverse cells. Lab Invest. 2001;81:1289–1297.
 65. Katabi N, Gomez D, Klimstra DS, Carlson DL, Lee N, Ghossein R. 
Prognostic factors of recurrence in salivary carcinoma ex pleomor-
phic adenoma, with emphasis on the carcinoma histologic subtype: a 
clinicopathologic study of 43 cases. Hum Pathol. 2010;41:927–934.
   | 11VALSTAR eT AL.
 66. Katabi N, Xu B, Jungbluth AA, et al. PLAG1 immunohistochem-
istry is a sensitive marker for pleomorphic adenoma: a compar-
ative study with PLAG1 genetic abnormalities. Histopathology. 
2018;72:285–293.
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section.
How to cite this article: Valstar MH, Schaapveld M, 
den Broek EC, et al. Risk of breast cancer in women 
after a salivary gland carcinoma or pleomorphic 
adenoma in the Netherlands. Cancer Med. 2020;00: 
1–11. https://doi.org/10.1002/cam4.3598
